Table 8.
Characteristics of CVID patients diagnosed with lymphoma.
| ID | Sex |
Age at cancer onset, years |
Age at CVID diagnosis, years | Survival after cancer, months | Outcome (cause) | Histology and stage | Treatment | Additional cancer |
|---|---|---|---|---|---|---|---|---|
| 6 | M | 50 | 37 | 216 | Alive | Diffuse large B cell lymphoma (small bowel) | Chemotherapy NOS | Gastric cancer |
| 10 | F | 32 | 42 | 336 | Alive | HD | CHOP, ABV | Gastric cancer |
| 13 | F | 67 | 35 | 12 | Deceased (gastric cancer) |
Diffuse large B cell lymphoma | NA | Gastric cancer |
| 26 | F | 47 | 47 | 8 | Deceased (lymphoma) | NHL not further classified | NA | No |
| 27 | M | 38 | 37 | 120 | Alive | Diffuse large B cell lymphoma of small bowel, stage IVE | R-CHOP | No |
| 28 | F | 50 | 44 | 13 | Deceased (lymphoma) |
T-cell lymphoma (peripheral T cell lymphoma) | CHOP, autologous HSCT, Brentuximab | No |
| 29 | F | 64 | 58 | 12 | Deceased (lymphoma) |
T-cell lymphoma (angioimmunoblastic T cell lymphoma) | Prednisone | No |
| 30 | M | 40 | 47 | 144 | Deceased (lymphoma) |
NHL not further classified | NA | No |
| 31 | M | 48 | 41 | 132 | Alive | NHL not further classified | NA | No |
| 32 | F | 74 | 47 | 24 | Alive | Diffuse large B cell lymphoma (large bowel) | R-CHOP, RTX | No |
| 33 | M | 53 | 47 | 9 | Alive | Diffuse large B cell lymphoma (T-cells rich) | R-CHOP | No |
| 34 | M | 29 | 30 | 14 | Alive | Diffuse large B cell lymphoma | R-CHOP | No |
| 35 | M | 58 | 55 | 36 | Alive | NHL not further classified | Chemotherapy NOS | No |
| 36 | M | 59 | 35 | 12 | Deceased (lymphoma) |
Cutaneous diffuse large B cell lymphoma leg-type | R-CHOP, radiotherapy | No |
| 37 | F | 67 | 43 | 84 | Alive | Marginal Zone Lymphoma (Splenic) | Splenectomy | Lung cancer |
| 38 | M | 54 | 47 | 84 | Alive | NHL not further classified | NA | No |
| 39 | F | 29 | 28 | 24 | Alive | Lymphoplasmacytic lymphoma | Chemotherapy NOS | No |
| 40 | M | 47 | 45 | 6 | Deceased (lymphoma) |
NHL not further classified | NA | No |
| 41 | F | 65 | 62 | 8 | Deceased (lymphoma) | Diffuse large B cell lymphoma | NA | No |
| 42 | F | 62 | 56 | 12 | Alive | Marginal Zone Lymphoma (nodal and extra nodal) | RTX, bendamustine | No |
| 43 | M | 60 | 60 | 36 | Alive | Marginal Zone Lymphoma (nodal and extra nodal) | R-CHOP | No |
| 44 | M | 47 | 47 | 72 | Alive | Anaplastic T cell Lymphoma ALK- stage IVB (skin) | CHOEP, FEAM and autologous HSCT | No |
| 45 | F | 67 | 64 | 11 | Deceased (lymphoma) | NHL not further classified | NA | No |
| 46 | F | 61 | 70 | 168 | Deceased (cardiovascular) |
Diffuse large B cell lymphoma (small bowel) | Ileocecal resection + R-CHOP | No |
| 47 | F | 41 | 38 | 24 | Alive | Marginal Zone Lymphoma | NA | No |
| 48 | M | 52 | 56 | 120 | Alive | NHL, not further classified, stage IV | R-FN, R-CHOP | No |
| 49 | M | 70 | 59 | 12 | Alive | Marginal Zone Lymphoma (nodal, indolent behavior) | Rituximab + bendamustine | Prostatic cancer |
| 50 | M | 41 | 40 | 15 | Alive | Kaposi sarcoma/Primitive effusion lymphoma, HHV8+/EBV+ | CDE | No |
| 51 | F | 74 | 62 | 72 | Alive | MALT Lymphoma (gastric) | NA | No |
| 52 | M | 59 | 59 | 60 | Deceased (lymphoma) | Diffuse large B cell lymphoma (lung), stage IVB | R-CHOP, R-COMP | No |
| 53 | F | 45 | 54 | 216 | Deceased (lymphoma) | NHL not further classified (low grade) | R-CHOP + Etoposide | Uterine cancer, body |
| 54 | M | 55 | 55 | 10 | Deceased (lymphoma) | NHL not further classified | NA | No |
| 55 | M | 36 | 21 | 108 | Alive | HD, classic type, stage IIIsB | ABVD | No |
| 56 | M | 30 | 28 | 12 | Deceased (lymphoma) |
HD, classical type, lymphocyte-depleted, stage IV | Chemotherapy NOS | Thyroid cancer |
| 57 | F | 28 | 38 | 12 | Deceased (T-cell lymphoma) |
HD, mixed-cellularity type | Radiotherapy | Thyroid cancer, angio-immunoblastic T cell lymphoma) |
| 58 | M | 29 | 18 | 8 | Alive | HD, sclero-nodular type | ABVD, radiotherapy | No |
| 59 | M | 39 | 38 | 96 | Deceased (lymphoma) |
HD, classical type, stage IVA | VEBEP, HSCT | No |
ABV, Adriamycin, Hydroxydaunorubicin, Bleomycin, Vinblastine; ABVD, Adriamycin, Hydroxydaunorubicin, Bleomycin, Vinblastine, Dacarbazine; CHOEP, Cyclophosphamide, Doxorubicin, Etoposide, Vincristine, Prednisone; CHOP, Cyclophosphamide, Hydroxydaunorubicin, Vincristine, Prednisone; CDE, Cyclophosphamide, Doxorubicin, Etoposide; COPP, Cyclophosphamide, Vincristine, Procarbazine, Prednisone; FEAM, Fotemustine, Etoposide, Cytarabine, Melphalan; R-CHOP, Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Vincristine, Prednisone; FN-R, Rituximab, Fludarabine, Mitoxantrone; HD, Hodgkin disease, NHL, Non-Hodgkin lymphoma, HSCT, Hematopoietic stem cell transplantation; R-COMP, Rituximab, Cyclophosphamide, Vincristine, Myocet, Prednisone; RTX, Rituximab; VEBEP, Etoposide, Epirubucin, Bleomycin, Cyclophosphamide, Prednisolone; NOS, not otherwise specified; NA, not available.